TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis
Production of Antibodies Against Tnf-alfa Blockers in Patients With Psoriasis
Lead SponsorUniversity of Copenhagen
Intervention/Treatmentetanercept adalimumab infliximab ...
TNF alfa blockers are widely used for treatment of severe psoriasis. These biologics are well-tolerated with few side effects.
Unfortunately not all patients respond adequately to treatment with tnf alfa blockers. Some do not respond at all while others respond initially but gradually lose effect despite increased dose and more frequent administration.
The cause of treatment failure is largely unknown and it may be production of tnf-alfa neutralizing antibodies. This has been demonstrated in patients with rheumatoid arthritis and inflammatory bowel disease who lost response after treatment with tnf-alfa blockers.
The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug. The study subjects will receive treatment with one drug only - infliximab or adalimumab or etanercept The consulting dermatologist decides which drug to use according to official guidelines
This arm includes all the patients of the study. They are patients who are start treatment with a tnf-alfa blocking drug
Inclusion Criteria: Male or female Age above 18 Psoriasis Indication for treatment with tnf alfa blocking drug Written informed consent obtained Exclusion Criteria: Severe psychiatric disorder No indication for treatment with tnf-alfa blocking drug Pregnancy Breastfeeding No written informed consent